Low Muscle Mass Emerges as a Powerful Predictor of Death in Cancer Patients

A sweeping analysis of more than 635,000 cancer patients in South Korea has delivered one of the clearest signals yet that what lies beneath the scale matters far more than the number itself. Researchers drawing on nationwide health insurance and cancer registry data found that people with low muscle mass faced a 25 percent higher risk of death from any cause after a cancer diagnosis, and the excess risk extended well beyond the cancer itself. Cardiovascular deaths were nearly half again as likely, and respiratory deaths were more than twice as common among patients in the lowest quartile of appendicular skeletal muscle mass. The findings, published in Cancer Causes & Control, challenge the long-standing habit of judging prognosis by body weight alone and suggest that body composition may be one of the most underused prognostic tools in oncology.

The study, led by Dagyeong Lee of Wonkwang University Sanbon Hospital and Sungkyunkwan University, together with biostatistician Kyungdo Han of Soongsil University and Dong Wook Shin of Samsung Medical Center, exploited a uniquely rich data infrastructure. South Korea’s National Health Insurance Service requires nearly all residents to attend periodic health screenings, during which body measurements and blood tests are collected, and the national cancer registry captures virtually every diagnosed malignancy in the country. By linking these systems, the team assembled a cohort of 635,867 adults who had been diagnosed with cancer and who had body composition data available around the time of diagnosis, allowing mortality outcomes to be tracked with unusual statistical power.

The technical backbone of the analysis was the appendicular skeletal muscle mass index, or ASMI, an estimate of the muscle contained in the arms and legs normalized to body size. Rather than relying on expensive imaging for every participant, the researchers used validated prediction equations that incorporate anthropometric measurements, serum creatinine levels and lifestyle factors, an approach previously validated in Korean adults. Patients falling in the lowest quartile of ASMI were classified as having low muscle mass, a definition aligned with the framework used by the Asian Working Group for Sarcopenia. Obesity was assessed two ways: a body mass index of 25 kilograms per square meter or higher, following Asia-Pacific criteria, and abdominal obesity defined as a waist circumference of at least 90 centimeters in men and 85 centimeters in women.

Using Cox proportional hazards regression, the team calculated adjusted hazard ratios that accounted for a broad range of potential confounders, including age, sex, smoking status, alcohol consumption, physical activity, income, comorbid conditions and cancer characteristics. Compared with patients in the highest ASMI quartile, those with low muscle mass showed a 25 percent higher risk of all-cause mortality, a 21 percent higher risk of dying specifically from cancer, a 49 percent higher risk of cardiovascular death and a startling 126 percent higher risk of respiratory death. The dose-response pattern was consistent: the less muscle a patient carried, the greater the mortality risk across every category examined.

Perhaps the most provocative result concerned the interaction between muscle and fat. Obesity, which is often assumed to be uniformly harmful in cancer patients, was actually associated with modestly lower mortality than non-obese status in this cohort, echoing the so-called obesity paradox reported in several cancer populations. But when low muscle mass and obesity coexisted, the protective veneer vanished. Patients with both conditions had the highest risks of all, with a 22 percent elevation in all-cause mortality and a 22 percent elevation in cancer-specific mortality compared with their counterparts. In other words, carrying extra fat did not rescue patients who lacked muscle; it appeared to compound their vulnerability.

This combination, often called sarcopenic obesity, has been recognized as a distinct clinical entity by international consensus statements from ESPEN and EASO in Europe and by an Asia-Oceania consortium, but its prognostic weight has been difficult to quantify because most prior studies were small, single-center or limited to specific tumor types. Meta-analyses of sarcopenia in solid tumors, including work in pancreatic, esophageal, lung and breast cancers, have consistently flagged poor outcomes, yet the new study is among the first to dissect cause-specific mortality at nationwide scale. By separating deaths due to cancer, cardiovascular disease and respiratory disease, the researchers revealed that muscle depletion is not merely a marker of advanced malignancy but a systemic risk factor operating across multiple organ systems.

The biological explanations are plausible and varied. Skeletal muscle is not an inert reservoir of protein; it is a metabolically active tissue that regulates glucose disposal, secretes anti-inflammatory myokines during contraction and serves as the body’s main amino acid store during illness. Cancer cachexia, the syndrome of muscle wasting that accompanies many malignancies, disrupts mitochondrial dynamics and promotes inflammation within muscle fibers, and low muscle mass is closely associated with elevated inflammatory markers such as erythrocyte sedimentation rate and low albumin. Depleted muscle also alters the pharmacokinetics of chemotherapy, potentially increasing toxicity, and predicts postoperative complications including pulmonary failure after esophagectomy and poor long-term outcomes in rectal cancer.

The respiratory findings deserve particular attention. Sarcopenia affects the diaphragm and intercostal muscles, compromising ventilatory capacity and cough strength, which helps explain why patients with low muscle mass were more than twice as likely to die from respiratory causes. Studies of cancer cachexia in animal models have documented diaphragm and ventilatory dysfunction, and clinical work has linked low muscle mass to severe dysphagia, raising aspiration risk. Meanwhile, the cardiovascular signal aligns with a growing literature showing that cardiovascular disease is a leading cause of death among long-term cancer survivors, driven partly by shared risk factors and partly by cardiotoxic treatments such as anthracycline chemotherapy, whose effects may be amplified in patients with depleted physiological reserve.

The authors emphasize that the practical message is not simply to gain weight but to build and preserve muscle. Clinical guidelines from the American Cancer Society already recommend that survivors maintain healthy weight through nutrition and physical activity, and randomized trials of combined aerobic and resistance training, along with dietary interventions, have shown meaningful improvements in body composition and cardiometabolic risk in patients with cancer. What the new study adds is a rationale for making muscle mass itself a routine clinical measurement at diagnosis, rather than an afterthought. Because the ASMI estimate can be derived from simple measurements already collected in health screenings, the barrier to implementation is low, particularly in health systems with structured screening programs.

Limitations remain. The cohort was exclusively Korean, and muscle mass thresholds and obesity criteria differ across populations, so the absolute risks may not translate directly to other ethnic groups. The prediction equations used to estimate ASMI, while validated, are less precise than direct imaging with computed tomography or dual-energy X-ray absorptiometry, and residual confounding by cancer stage, treatment intensity and unmeasured lifestyle factors cannot be excluded. The observational design means causality cannot be proven. Still, with more than 635,000 patients and consistent, graded associations across every cause of death examined, the study makes a compelling case that the scale tells only half the story. For oncologists and survivors alike, the takeaway is increasingly clear: in the fight against cancer, muscle is not optional equipment, and protecting it may be one of the most actionable steps available for extending survival.

Subject of Research: The association of low muscle mass and obesity with cause-specific mortality in cancer patients

Article Title: Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study

Article References: Lee, D., Kim, B., Jung, K.-W., Nam, G. E., Rhee, S. Y., Kim, S., Chun, S., Cho, I. Y., Han, K., & Shin, D. W. (2026). Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study. Cancer Causes & Control, 37(10), Article 156. https://doi.org/10.1007/s10552-026-02244-y

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02244-y

Keywords: low muscle mass, sarcopenia, sarcopenic obesity, cancer mortality, obesity paradox, body composition, cancer survivors, cardiovascular mortality, respiratory mortality, nationwide cohort study, ASMI, cancer prognosis